Search

Your search keyword '"Noel, Anne-Laure"' showing total 3 results
Start Over Author "Noel, Anne-Laure" Topic 0301 basic medicine
3 results on '"Noel, Anne-Laure"'

1. Detection of arboviruses in mosquitoes: Evidence of circulation of chikungunya virus in Iran

Author

Marie Vazeille, Géraldine Piorkowski, Hasan Bakhshi, Sara Moutailler, Xavier de Lamballerie, Navid Dinparast-Djadid, Laurence Mousson, Anna-Bella Failloux, Sedigheh Zakeri, Abbasali Raz, Malaria and Vector Research Group (MVRG), Institut Pasteur d'Iran, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Arbovirus et Insectes Vecteurs - Arboviruses and Insect Vectors, Institut Pasteur [Paris] (IP), Biologie moléculaire et immunologie parasitaires et fongiques (BIPAR), École nationale vétérinaire - Alfort (ENVA)-Laboratoire de santé animale, sites de Maisons-Alfort et de Normandie, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Unité des Virus Emergents (UVE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), European Project: 734548,ZIKAlliance(2016), Noel, Anne-Laure, A global alliance for Zika virus control and prevention - ZIKAlliance - 2016-10-01 - 2019-09-30 - 734548 - VALID, Institut Pasteur [Paris], École nationale vétérinaire d'Alfort (ENVA)-Laboratoire de santé animale, sites de Maisons-Alfort et de Dozulé, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Aix Marseille Université (AMU)-Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM), and École nationale vétérinaire - Alfort (ENVA)-Laboratoire de santé animale, sites de Maisons-Alfort et de Dozulé

Subjects
0301 basic medicine, Male, RNA viruses, Viral Diseases, viruses, RC955-962, Dengue virus, Iran, Disease Vectors, medicine.disease_cause, Pathology and Laboratory Medicine, Mosquitoes, Geographical Locations, Human health, 0302 clinical medicine, Arctic medicine. Tropical medicine, Genotype, Screening method, Medicine and Health Sciences, Chikungunya, [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Chikungunya Virus, biology, virus diseases, Eukaryota, 3. Good health, Insects, Infectious Diseases, Medical Microbiology, Arboviral Infections, Viral Pathogens, Viruses, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Female, Public aspects of medicine, RA1-1270, Pathogens, West Nile virus, Research Article, Neglected Tropical Diseases, Asia, Arthropoda, Alphaviruses, 030231 tropical medicine, Microbiology, Virus, Togaviruses, 03 medical and health sciences, Culex pipiens, parasitic diseases, medicine, Animals, Microbial Pathogens, Flaviviruses, Public Health, Environmental and Occupational Health, Organisms, Biology and Life Sciences, Chikungunya Infection, Dengue Virus, biology.organism_classification, Tropical Diseases, Virology, Invertebrates, Insect Vectors, Species Interactions, 030104 developmental biology, Culicidae, People and Places, Anopheles maculipennis, Arboviruses
Abstract

Mosquitoes are vectors of viruses affecting animal and human health. In Iran, the prevalence of mosquito-borne viruses remains poorly investigated. Once infected, mosquito females remain infected for all their life making virus detections possible at early steps before infections are reported in vertebrate hosts. In this study, we used a recently developed high-throughput chip based on the BioMark Dynamic arrays system capable of detecting 37 arboviruses in a single experiment. A total of 1,212 mosquitoes collected in Mazandaran, North-Khorasan, and Fars provinces of Iran were analyzed. Eighteen species were identified, belonging to five genera; the most prevalent species were Anopheles maculipennis s.l. (42.41%), Culex pipiens (19.39%), An. superpictus (11.72%), and Cx. tritaeniorhynchus (10.64%). We detected chikungunya virus (CHIKV) of the Asian genotype in six mosquito pools collected in North Khorasan and Mazandaran provinces. To our knowledge, this is the first report of mosquitoes infected with CHIKV in Iran. Our high-throughput screening method can be proposed as a novel epidemiological surveillance tool to identify circulating arboviruses and to support preparedness to an epidemic in animals and humans., Author summary Mosquito-borne viruses pose a serious threat to public health worldwide. For an efficient preparedness to future emergences, an early detection of arboviruses in vector populations would be wise before animal/human cases arise. Here, we used a recently developed high-throughput chip based on the BioMark Dynamic arrays system, capable of screening various arboviruses in a single experiment. By examining 1,212 mosquitoes collected in Iran, we provide evidence that chikungunya virus is circulating in Iran.

Published
2020
Full Text
View/download PDF

2. Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs

Author

Cyril Gaudin, Stefan Niemann, Alice Ferré, Stéphanie Duthoy, Vanessa Mathys, Yannick Laurent, Emmanuel André, Elisa Tagliani, Bouke C. de Jong, Philip Supply, Andrea M. Cabibbe, Silke Feuerriegel, Caroline Allix-Béguec, Nelly Badalato, Sandy Contreras, Michel K. Kaswa, Leen Rigouts, Agathe Jouet, Daniela Maria Cirillo, Maren Diels, Institute of Tropical Medicine [Antwerp] (ITM), Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Universiteit Antwerpen [Antwerpen], Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Genoscreen [Lille], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Forschungszentrum Borstel - Research Center Borstel, German Centre for Infection Research - partner site Hamburg-Lübeck-Borstel-Riems (DZIF), National Tuberculosis Program [Kinshasa], IRCCS Ospedale San Raffaele [Milan, Italy], Maladies bactériennes = Bacterial diseases [Bruxelles], Sciensano [Bruxelles], Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Parts of this work have been supported by the European Union PathoNGen-Trace project (FP7-278864) and by the World Health Organization (for the TB drug resistance survey conducted in the Democratic Republic of the Congo). B.C. de Jong and L. Rigouts were supported by European Research Council starting grant 'INTERRUPTB' (grant agreement 311725)., European Project: 278864,EC:FP7:HEALTH,FP7-HEALTH-2011-two-stage,PATHONGEN-TRACE(2012), European Project: 311725,EC:FP7:ERC,ERC-2012-StG_20111109,INTERRUPTB(2013), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL], Universiteit Antwerpen = University of Antwerpen [Antwerpen], Noel, Anne-Laure, Next Generation Genome Based High Resolution Tracing of Pathogens - PATHONGEN-TRACE - - EC:FP7:HEALTH2012-01-01 - 2016-06-30 - 278864 - VALID, and Estimating the effective reproductive rate of M. tuberculosis from changes in molecular clustering rates, to measure the impact of public health interventions on TB transmission - INTERRUPTB - - EC:FP7:ERC2013-01-01 - 2017-12-31 - 311725 - VALID

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, 030106 microbiology, Respiratory System, Antitubercular Agents, Drug resistance, Microbial Sensitivity Tests, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Deep sequencing, Mycobacterium, 03 medical and health sciences, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Tuberculosis, Multidrug-Resistant, medicine, Humans, Tuberculosis, Deeplex Myc-TB may enable fast, Ethambutol, Genetics, Whole genome sequencing, Science & Technology, biology, business.industry, High-Throughput Nucleotide Sequencing, Original Articles, Mycobacterium tuberculosis, Pyrazinamide, biology.organism_classification, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, 030104 developmental biology, Mycobacterium tuberculosis complex, Pharmaceutical Preparations, Pulmonary Infections and Tuberculosis, Mutation, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Ethionamide, tailored tuberculosis treatment, Human medicine, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, business, Life Sciences & Biomedicine, Rifampicin, medicine.drug
Abstract

Conventional molecular tests for detecting Mycobacterium tuberculosis complex (MTBC) drug resistance on clinical samples cover a limited set of mutations. Whole-genome sequencing (WGS) typically requires culture. Here, we evaluated the Deeplex Myc-TB targeted deep-sequencing assay for prediction of resistance to 13 anti-tuberculous drugs/drug classes, directly applicable on sputum. With MTBC DNA tests, the limit of detection was 100–1000 genome copies for fixed resistance mutations. Deeplex Myc-TB captured in silico 97.1–99.3% of resistance phenotypes correctly predicted by WGS from 3651 MTBC genomes. On 429 isolates, the assay predicted 92.2% of 2369 first- and second-line phenotypes, with a sensitivity of 95.3% and a specificity of 97.4%. 56 out of 69 (81.2%) residual discrepancies with phenotypic results involved pyrazinamide, ethambutol and ethionamide, and low-level rifampicin or isoniazid resistance mutations, all notoriously prone to phenotypic testing variability. Only two out of 91 (2.2%) resistance phenotypes undetected by Deeplex Myc-TB had known resistance-associated mutations by WGS analysis outside Deeplex Myc-TB targets. Phenotype predictions from Deeplex Myc-TB analysis directly on 109 sputa from a Djibouti survey matched those of MTBSeq/PhyResSE/Mykrobe, fed with WGS data from subsequent cultures, with a sensitivity of 93.5/98.5/93.1% and a specificity of 98.5/97.2/95.3%, respectively. Most residual discordances involved gene deletions/indels and 3–12% heteroresistant calls undetected by WGS analysis or natural pyrazinamide resistance of globally rare “Mycobacterium canettii” strains then unreported by Deeplex Myc-TB. On 1494 arduous sputa from a Democratic Republic of the Congo survey, 14 902 out of 19 422 (76.7%) possible susceptible or resistance phenotypes could be predicted culture-free. Deeplex Myc-TB may enable fast, tailored tuberculosis treatment., The novel Deeplex Myc-TB molecular assay shows a high degree of accuracy for extensive prediction of susceptibility and resistance to 13 anti-tuberculous drugs, directly achievable without culture, which may enable fast, tailored tuberculosis treatment https://bit.ly/3bAvcAt

Published
2020
Full Text
View/download PDF

3. Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic : GEMO position paper

Author

Jean-Jacques Body, Frédéric Lecouvet, Marie-Hélène Vieillard, F. Paycha, Francesco Giammarile, Martine Duterque-Coquillaud, Jean Christophe Faivre, Sébastien Thureau, Cyrille B. Confavreux, Laetitia Morardet, Françoise Debiais, Dominique Heymann, Emmanuel Biver, Richard Assaker, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Geneva University Hospital (HUG), University of Geneva [Switzerland], Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de rhumatologie [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 (CANTHER), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain = Catholic University of Louvain (UCL), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire Brugmann [Bruxelles] (CHU), Equipe Quantification en Imagerie Fonctionnelle [QuantIF-LITIS], Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes [LITIS], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] [UNICANCER/ICL], Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille], Service de rhumatologie[Lille], Institut de biologie de Lille - IBL [IBLI], Centre de Recherche en Cancérologie et Immunologie Nantes-Angers [CRCINA], Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO], Institut de Recherche Expérimentale et Clinique [IREC], Université Catholique de Louvain = Catholic University of Louvain [UCL], Centre Hospitalier Universitaire Brugmann [Bruxelles] [CHU], Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA), Hôpital Roger Salengro [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hospices Civils de Lyon (HCL), Institut de biologie de Lille - IBL (IBLI), Université de Lille, Sciences et Technologies-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Université de Lille, Droit et Santé-Centre National de la Recherche Scientifique (CNRS), Université Catholique de Louvain (UCL), Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Noel, Anne-Laure, Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Université de Genève = University of Geneva (UNIGE), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]

Subjects
0301 basic medicine, [SDV.MHEP.AHA] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], medicine.medical_specialty, Respiratory complications, lcsh:Diseases of the musculoskeletal system, Palliative Radiation Therapy, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, [SDV]Life Sciences [q-bio], [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], lcsh:RC254-282, 03 medical and health sciences, [SDV.MHEP.PED] Life Sciences [q-bio]/Human health and pathology/Pediatrics, 0302 clinical medicine, [SDV.CAN] Life Sciences [q-bio]/Cancer, Biopsychologie et psychopathologie, Pandemic, Health care, [SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB], [SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO], Medicine, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, ddc:616, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, business.industry, Neurosciences cognitives, Cancer, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, 3. Good health, Radiation therapy, 030104 developmental biology, Oncology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 030220 oncology & carcinogenesis, Position paper, lcsh:RC925-935, business
Abstract

The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results